Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease

Hyperkalemia (serum potassium [K+] ≥5.1) is life-threatening in patients diagnosed with end stage kidney disease (ESKD). Patiromer is approved for the treatment of hyperkalemia, although its role in hyperkalemic patients with ESKD is not well understood. This study describes real-world patiromer uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinnell, Derek, Patel, Shardool, Qualls, Joshua, Chen, Wei, Rathod, Anitha, Woods, Steven D., Boutin, Sylvie, Kovesdy, Csaba P., Tangri, Navdeep, Sauer, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771256/
https://www.ncbi.nlm.nih.gov/pubmed/36550897
http://dx.doi.org/10.1097/MD.0000000000032367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771256/
https://www.ncbi.nlm.nih.gov/pubmed/36550897
http://dx.doi.org/10.1097/MD.0000000000032367

Ejemplares similares